Systemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

(2021) Corinne Faivre-Finn et al.   Journal of Thoracic Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

(2021) Jacqueline V. Aredo et al.   Journal of Thoracic Oncology

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

(2021) Marina C Garassino et al.   Future Oncology

Assessment of a Contralateral Esophagus–Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation

(2021) Sophia C. Kamran et al.   JAMA Oncology

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)

(2021) Mark A. Socinski et al.   Clinical Lung Cancer

NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).

(2021) Feng-Ming Spring Kong et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

(2021) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

(2021) Salma K. Jabbour et al.   JAMA Oncology

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

(2020) Stephan Rheinheimer et al.   Cancers

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression

(2020) Siddharth Sheth et al.   Journal for ImmunoTherapy of Cancer

Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer

(2020) Katelyn M. Atkins et al.   JAMA Oncology

Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions

(2020) Kathryn Banfill et al.   Journal of Thoracic Oncology

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib

(2019) A J Schoenfeld et al.   ANNALS OF ONCOLOGY

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer

(2019) Katelyn M. Atkins et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)

(2019) D. Raben et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

(2019) Jhanelle E. Gray et al.   Journal of Thoracic Oncology

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

(2019) Jeffrey D. Bradley et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer

(2019) Brian C. Baumann et al.   JAMA Oncology

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer

(2017) Kristin A. Higgins et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

(2017) Kyle Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

(2017) Stephen G. Chun et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

(2017) Aadel A. Chaudhuri et al.   Cancer Discovery

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2016) Suresh Senan et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Quality of Life Analysis of a Radiation Dose–Escalation Study of Patients With Non–Small-Cell Lung Cancer

(2016) Benjamin Movsas et al.   JAMA Oncology

Intensity Modulated Radiation Therapy is Associated With Improved Survival in Non-Small Cell Lung Cancer With Advanced T Stage: Results From the National Cancer Data Base

(2015) N. Jegadeesh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

(2015) Jin Seok Ahn et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer

(2015) Megan E. Daly et al.   Journal of Thoracic Oncology

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

(2015) Rogerio Lilenbaum et al.   Journal of Thoracic Oncology

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

(2015) Jeffrey D Bradley et al.   LANCET ONCOLOGY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?

(2013) Neil Bayman et al.   LUNG CANCER

Radiation-induced effects and the immune system in cancer

(2012) Punit Kaur et al.   Frontiers in Oncology

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

(2011) W. J. Curran et al.   JNCI-Journal of the National Cancer Institute

Rapid Disease Progression With Delay in Treatment of Non–Small-Cell Lung Cancer

(2010) Nasiruddin Mohammed et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non–Small-Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515

(2010) Jeffrey Bradley et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer

(2010) Anne Aupérin et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy

(2009) Zhongxing X. Liao et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

(2008) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

(2008) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY